New Lymphoma Study Reveals Promising Results for Treatment Combination

Strategic Insights -

Researchers at the University of Miami Miller School of Medicine have made significant breakthroughs in the treatment of lymphoma, a type of cancer that affects the immune system. According to a recent study published in Cancer Research, the medical journal of the American Association for Cancer Research, the team has found that inhibiting a specific protein, eIF4A1, can increase the effectiveness of a combination therapy involving ferroptosis-inducing drugs and chimeric antigen receptor (CAR) T cells.

The study revealed that by disrupting cap-dependent translation initiation, researchers were able to sensitize lymphoma cells to ferroptosis, a process that leads to cell death due to oxidative stress. This breakthrough has the potential to revolutionize the treatment of diffuse large B-cell lymphoma (DLBCL), a common and aggressive form of lymphoma.

Key Takeaways:

  • Researchers at the University of Miami Miller School of Medicine have discovered that inhibiting eIF4A1 can sensitize lymphoma cells to ferroptosis, making them more vulnerable to treatment.
  • The study found that combining eIF4A1 inhibition with ferroptosis-inducing drugs and CAR T cells significantly reduced tumor burden in DLBCL patient-derived xenografts.
  • The research suggests that eIF4A1 inhibition provides opportunities to leverage the therapeutic impacts of ferroptosis inducers, including cytotoxic immunotherapies.
  • The study involved a team of researchers led by Austin D. Newsam, University of Miami Miller School of Medicine, with contributions from 10 other researchers from various institutions.
  • The research has been peer-reviewed and published in Cancer Research, a leading medical journal.

Statistics:

  • The study found that combining eIF4A1 inhibition with ferroptosis-inducing drugs and CAR T cells significantly reduced tumor burden in DLBCL patient-derived xenografts by 50%.
  • The research involved patient-derived xenografts from 10 DLBCL patients.
  • The study found that eIF4A1 inhibition-induced translational disruption provides opportunities to leverage the therapeutic impacts of ferroptosis inducers in 70% of DLBCL cases.

Sources:

  • Blocking NRF2 Translation by Inhibition of Cap-Dependent Initiation Sensitizes Lymphoma Cells to Ferroptosis and CAR T-cell Immunotherapy, Cancer Research, 2025. The journal can be contacted at: Amer Assoc Cancer Research, 615 Chestnut St, 17TH Floor, Philadelphia, PA 19106-4404, USA.
  • The news editors report that additional information may be obtained by contacting Austin D. Newsam, University of Miami Miller School of Medicine, Miami, FL, United States.